Imunon +$0 +0% Thursday 15:02
1D 1W 1M 3M 1Y 5Y
11 Nov Expected
This list is based on the watchlists of people on Stock Events who follow 0HUZ.LSE. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap 98.35B
Gilead Sciences is a biopharmaceutical company that competes with Imunon in the development of treatments for infectious diseases, including HIV and hepatitis, areas where Imunon also aims to innovate.
Merck & Co. is involved in the discovery, development, manufacturing, and marketing of pharmaceuticals, including cancer treatments and vaccines, directly competing with Imunon's focus on oncology and immunotherapy. Bristol-Myers Squibb
BMY
Mkt Cap 101.27B
Bristol Myers Squibb operates in the same biopharmaceutical space as Imunon, focusing on cancer, HIV/AIDS, cardiovascular disease, and immune disorders, making it a direct competitor.
Amgen is a biotech company focusing on human therapeutics, including treatments for cancer and inflammatory diseases, competing with Imunon's research and development in similar areas.
Pfizer is a global pharmaceutical corporation that competes with Imunon in the development and marketing of drugs and vaccines for a wide range of diseases, including those targeted by Imunon's pipeline. Novartis
NVS
Mkt Cap 244.75B
Novartis is a global healthcare company that competes with Imunon in developing innovative medicines for various diseases, including cancer and autoimmune diseases, areas of focus for Imunon.
Roche Holding AG is a healthcare company that competes with Imunon in the fields of pharmaceuticals and diagnostics, particularly in oncology and immunology.
AbbVie is a research-based biopharmaceutical company that competes with Imunon in developing therapies for complex and serious diseases, including cancer and immune-mediated diseases. Johnson & Johnson
JNJ
Mkt Cap 399.26B
Johnson & Johnson is a diversified healthcare company that competes with Imunon across several areas, including pharmaceuticals and research and development in immunology and oncology. Regeneron Pharmaceuticals
REGN
Mkt Cap 130.59B
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of medicines for serious medical conditions, competing with Imunon in the area of immunotherapy and targeted cancer treatments.
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Show more...
CEO
Mr. Michael H. Tardugno
